公开(公告)号：US20150299281A1

公开(公告)日：2015-10-22

申请号：US14398260

申请日：2013-05-03

申请人： Zealand Pharma A/S/

发明人： Rasmus JUST ,  Ditte RIBER ,  Anne Pernille Tofteng SHELTON ,  Torben ØSTERLUND ,  Kate HANSEN ,  Lene JESSEN

IPC分类号： C07K14/575

CPC分类号： C07K14/575 ,  A61K38/00 ,  C07K14/605

摘要： The present invention relates to truncated GIP analogues which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.

摘要翻译： 本发明涉及与野生型GIP相比包含一个或多个取代并且其具有改变的，优选增加的GLP-1活性的性质的截短的GIP类似物，例如， 如在体外功效测定中评估的。 本发明提供GIP-GLP-1双重激动剂化合物和相关方法。

公开(公告)号：US20160355563A1

公开(公告)日：2016-12-08

申请号：US15238126

申请日：2016-08-16

申请人： Zealand Pharma A/S

发明人： Rasmus JUST ,  Kirsten Lindegaard BOVBJERG ,  Ditte RIBER ,  Wayne Shaun RUSSELL

IPC分类号： C07K14/605

CPC分类号： C07K14/605 ,  A61K35/22 ,  A61K35/48 ,  A61K35/54 ,  A61K35/63 ,  A61K35/64 ,  A61K38/26 ,  A61K45/06

摘要： GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogues are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.

摘要翻译： 公开了GLP-2类似物，其包含与h [Gly2] GLP-2相比更多的取代，并且其可具有改变的GLP-1活性的性质及其医疗用途。 类似物对于预防性治疗或改善糖尿病的胃肠相关副作用特别有用。

公开(公告)号：US20210115104A1

公开(公告)日：2021-04-22

申请号：US16986790

申请日：2020-08-06

申请人： Zealand Pharma A/S

发明人： Rasmus JUST ,  Oliver DEMMER ,  Lise GIEHM ,  Jesper Skodborg VILLADSEN ,  Henrik MUNCH ,  Jesper Mosolff MATHIESEN ,  Jolanta SKARBALIENE ,  Maria DERYABINA ,  Dieter Wolfgang HAMPRECHT

IPC分类号： C07K14/575 ,  C07K14/47

摘要： The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

公开(公告)号：US20190055296A1

公开(公告)日：2019-02-21

申请号：US15983822

申请日：2018-05-18

申请人： Zealand Pharma A/S

发明人： Jakob Lind TOLBORG ,  Keld FOSGERAU ,  Pia NØRREGAARD ,  Rasmus JUST ,  Ditte RIBER ,  Dieter Wolfgang HAMPRECHT ,  Robert AUGUSTIN ,  Leo THOMAS ,  Wolfgang RIST

IPC分类号： C07K14/605 ,  A61K38/26 ,  A61K45/06

摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

公开(公告)号：US20190135886A1

公开(公告)日：2019-05-09

申请号：US16121745

申请日：2018-09-05

申请人： Zealand Pharma A/S

发明人： Rasmus JUST ,  Ditte RIBER ,  Anne Pernille Tofteng SHELTON ,  Torben ØSTERLUND ,  Kate HANSEN ,  Lene JESSEN

IPC分类号： C07K14/575 ,  C07K14/605

摘要： The present invention relates to truncated GIP analogues which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.

公开(公告)号：US20160272693A1

公开(公告)日：2016-09-22

申请号：US15074526

申请日：2016-03-18

申请人： Zealand Pharma A/S ,  Boehringer Ingelheim International GmbH

发明人： Rasmus JUST ,  Oliver DEMMER ,  Lise GIEHM ,  Jesper Sloth VILLADSEN ,  Henrik MUNCH ,  Jesper Mosolff MATHIESEN ,  Jolanta SKARBALIENE ,  Maria DERYABINA ,  Dieter Wolfgang HAMPRECHT

IPC分类号： C07K14/575

摘要： The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

摘要翻译： 本发明涉及胰岛淀粉样多肽类似物及其在治疗或预防各种疾病，病症或障碍（包括肥胖症，过量食物摄取和相关代谢疾病如糖尿病）中的用途。 类似物具有良好的物理和化学稳定性，良好的溶解性和长的作用时间，并且非常适合以液体制剂的形式使用。

公开(公告)号：US20160009777A1

公开(公告)日：2016-01-14

申请号：US14864256

申请日：2015-09-24

申请人： ZEALAND PHARMA A/S

发明人： Jakob Lind TOLBORG ,  Keld FOSGERAU ,  Pia NØRREGAARD ,  Rasmus JUST ,  Ditte RIBER ,  Dieter Wolfgang HAMPRECHT ,  Robert AUGUSTIN ,  Leo THOMAS ,  Wolfgang RIST

IPC分类号： C07K14/605 ,  A61K45/06 ,  A61K38/26

CPC分类号： C07K14/605 ,  A61K38/26 ,  A61K45/06

摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

公开(公告)号：US20210363213A1

公开(公告)日：2021-11-25

申请号：US17388328

申请日：2021-07-29

申请人： Zealand Pharma A/S

发明人： Rasmus JUST ,  Ditte RIBER ,  Anne Pernille Tofteng SHELTON ,  Torben ØSTERLUND ,  Kate HANSEN ,  Lene JESSEN

IPC分类号： C07K14/605

摘要： The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.

公开(公告)号：US20190270789A1

公开(公告)日：2019-09-05

申请号：US16151603

申请日：2018-10-04

申请人： Zealand Pharma A/S

发明人： Rasmus JUST ,  Ditte RIBER ,  Anne Pernille Tofteng SHELTON ,  Torben ØSTERLUND ,  Kate HANSEN ,  Lene JESSEN

IPC分类号： C07K14/605

摘要： The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.

公开(公告)号：US20180298077A1

公开(公告)日：2018-10-18

申请号：US15950235

申请日：2018-04-11

申请人： Zealand Pharma A/S

发明人： Rasmus JUST ,  Kirsten Lindegaard BOVBJERG ,  Ditte RIBER ,  Wayne Shaun RUSSELL

IPC分类号： C07K14/605 ,  A61K45/06 ,  A61K35/54 ,  A61K35/48 ,  A61K35/64 ,  A61K38/26 ,  A61K35/63 ,  A61K35/22

CPC分类号： C07K14/605 ,  A61K35/22 ,  A61K35/48 ,  A61K35/54 ,  A61K35/63 ,  A61K35/64 ,  A61K38/26 ,  A61K45/06

摘要： GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogues are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.